Barclays Maintains Underweight on NOV, Lowers Price Target to $13
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Barclays analyst David Anderson maintains NOV (NYSE:NOV) with a Underweight and lowers the price target from $14 to $13.
Barclays analyst David Anderson maintains NOV (NYSE:NOV) with a Underweight and lowers the price target from $14 to $13.